Radiomedix, Inc. Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Based in Houston, Texas, RadioMedix, Inc. operates in the biotechnology research sector with a focus on targeted radiopharmaceuticals for cancer diagnosis, monitoring, and therapy. The company commercializes generator-produced radiopharmaceuticals built on Gallium-68 chemistry and is advancing a late-stage program, GlucoMedix, a radiolabeled analogue that targets a metabolic pathway, leveraging its DO2A-chelation technology. These efforts sit at the intersection of diagnostic imaging and targeted radiotherapy, aiming to enable more precise cancer assessment and treatment.

It serves academic and industrial partners through two facilities: a cGMP manufacturing suite for clinical probe development and a molecular imaging facility for evaluating agents in animal models. In addition, the company has launched SmartMedix, an automated laboratory system designed to synthesize PET tracers for both research and clinical use. A notable development is a licensing agreement with Sanofi in September 2024 to expand access to radioligand therapy, reflecting RadioMedix’s active role in the field.

Sign up for free to view info

Company overview Employee directory